BR112022019167A2 - Inteínas split e usos das mesmas - Google Patents
Inteínas split e usos das mesmasInfo
- Publication number
- BR112022019167A2 BR112022019167A2 BR112022019167A BR112022019167A BR112022019167A2 BR 112022019167 A2 BR112022019167 A2 BR 112022019167A2 BR 112022019167 A BR112022019167 A BR 112022019167A BR 112022019167 A BR112022019167 A BR 112022019167A BR 112022019167 A2 BR112022019167 A2 BR 112022019167A2
- Authority
- BR
- Brazil
- Prior art keywords
- split inteins
- inteins
- split
- degrons
- combining
- Prior art date
Links
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000001687 destabilization Effects 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000017730 intein-mediated protein splicing Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382236.6A EP3885440A1 (en) | 2020-03-26 | 2020-03-26 | Split inteins and their uses |
| PCT/EP2021/058016 WO2021191447A1 (en) | 2020-03-26 | 2021-03-26 | Split inteins and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022019167A2 true BR112022019167A2 (pt) | 2022-11-01 |
Family
ID=70292931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022019167A BR112022019167A2 (pt) | 2020-03-26 | 2021-03-26 | Inteínas split e usos das mesmas |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230116688A1 (enExample) |
| EP (2) | EP3885440A1 (enExample) |
| JP (1) | JP2023518596A (enExample) |
| KR (1) | KR20220160052A (enExample) |
| CN (1) | CN115698307A (enExample) |
| AU (1) | AU2021241899A1 (enExample) |
| BR (1) | BR112022019167A2 (enExample) |
| CA (1) | CA3175696A1 (enExample) |
| IL (1) | IL296712A (enExample) |
| WO (1) | WO2021191447A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019336245B2 (en) | 2018-09-07 | 2026-02-26 | Beam Therapeutics Inc. | Compositions and methods for delivering a nucleobase editing system |
| CA3152679A1 (en) * | 2019-08-28 | 2021-03-04 | The Trustees Of Princeton University | Atypical split inteins and uses thereof |
| CN116096905A (zh) | 2020-02-21 | 2023-05-09 | 阿库斯股份有限公司 | 用于治疗人受试者的非年龄相关性听力损伤的组合物和方法 |
| EP4424714A4 (en) * | 2021-10-29 | 2025-10-15 | Shanghai Sinobay Biotechnology Co Ltd | Condition-Controlled Splicable Chimeric Antigen Receptor Molecule and Its Use |
| EP4527933A4 (en) * | 2022-05-17 | 2025-12-24 | Eye & Ent Hospital Of Fudan Univ | DUAL-SUPPORT SYSTEM FOR THE TREATMENT OF HEARING LOSS, AND ITS USE |
| KR20250141200A (ko) * | 2023-02-01 | 2025-09-26 | 알렌 인스티튜트 | 전압-게이팅 나트륨 채널 기능의 인테인 매개 재구성 |
| WO2024251077A1 (zh) | 2023-06-07 | 2024-12-12 | 北京中因科技有限公司 | 表达盒组合及其应用 |
| WO2025038955A1 (en) * | 2023-08-16 | 2025-02-20 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Systems and methods for improving safety of split intein aav mediated gene therapy |
| AU2024338787A1 (en) | 2023-09-04 | 2026-03-19 | Splicebio, Sl | Use of split intein for the treatment of scn1a associated disease |
| WO2025153705A1 (en) | 2024-01-18 | 2025-07-24 | Splicebio, Sl | Use of split intein for the treatment of myo7a-associated disease |
| WO2025193938A1 (en) * | 2024-03-13 | 2025-09-18 | Oregon Health & Science University | Delivery of type iv collagen alpha chain using a split intein dual aav vector |
| WO2026013288A1 (en) | 2024-07-12 | 2026-01-15 | Splicebio, Sl | Split intein for use in the treatment of cep290-associated disease |
| WO2026057767A1 (en) | 2024-09-13 | 2026-03-19 | Splicebio, Sl | Use of split intein for the treatment of abca3-associated disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5100792A (en) | 1984-11-13 | 1992-03-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| WO2007127428A2 (en) | 2006-04-28 | 2007-11-08 | University Of Florida Research Foundation, Inc. | Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery |
| US20180327779A1 (en) * | 2015-03-03 | 2018-11-15 | Fondazione Telethon (IT/IT) | Multiple vector system and uses thereof |
| US11203621B2 (en) * | 2015-06-19 | 2021-12-21 | Riken | PH-responsive proteolysis probe |
| WO2017132580A2 (en) * | 2016-01-29 | 2017-08-03 | The Trustees Of Princeton University | Split inteins with exceptional splicing activity |
| JP2022512718A (ja) * | 2018-10-15 | 2022-02-07 | フォンダッツィオーネ・テレソン | インテインタンパク質及びその使用 |
-
2020
- 2020-03-26 EP EP20382236.6A patent/EP3885440A1/en active Pending
-
2021
- 2021-03-26 JP JP2022558063A patent/JP2023518596A/ja active Pending
- 2021-03-26 IL IL296712A patent/IL296712A/en unknown
- 2021-03-26 KR KR1020227037261A patent/KR20220160052A/ko active Pending
- 2021-03-26 CA CA3175696A patent/CA3175696A1/en active Pending
- 2021-03-26 CN CN202180038835.4A patent/CN115698307A/zh active Pending
- 2021-03-26 US US17/914,212 patent/US20230116688A1/en active Pending
- 2021-03-26 AU AU2021241899A patent/AU2021241899A1/en active Pending
- 2021-03-26 BR BR112022019167A patent/BR112022019167A2/pt unknown
- 2021-03-26 EP EP21713447.7A patent/EP4127194A1/en active Pending
- 2021-03-26 WO PCT/EP2021/058016 patent/WO2021191447A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023518596A (ja) | 2023-05-02 |
| IL296712A (en) | 2022-11-01 |
| CN115698307A (zh) | 2023-02-03 |
| US20230116688A1 (en) | 2023-04-13 |
| AU2021241899A1 (en) | 2022-10-06 |
| KR20220160052A (ko) | 2022-12-05 |
| EP4127194A1 (en) | 2023-02-08 |
| WO2021191447A1 (en) | 2021-09-30 |
| EP3885440A1 (en) | 2021-09-29 |
| CA3175696A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022666A2 (pt) | Frações de separação e seus métodos e uso | |
| BR112021023048A2 (pt) | Moléculas de ligação a cd19 e usos das mesmas | |
| MX2021009357A (es) | Dianas de genes de combinacion para mejorar la inmunoterapia. | |
| MX2020009371A (es) | Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión. | |
| BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
| BR112021024127A2 (pt) | Adenovírus modificado | |
| BR112018009098A8 (pt) | métodos e composições para edição genética em células-tronco hematopoiéticas | |
| BR112022008201A2 (pt) | Degradação de proteínas de superfície usando agente de ligação biespecífico | |
| MX2021015614A (es) | Enzimas variantes de sacarosa fosforilasa modificadas geneticamente. | |
| BR112014017814A8 (pt) | Anticorpos anti-cxcr3 | |
| AR123005A1 (es) | Moléculas quiméricas que proveen coestimulación direccionada útil para terapia celular adoptiva | |
| BR112021019570A2 (pt) | Proteína de fusão, imunoconjugado, ácido nucleico isolado, vetor, célula, composição, uso dos mesmos para tratar um tumor, bem como métodos para preparar a proteína de fusão, para bloquear a interação entre a proteína pd-l1 e pd-1 e entre cd47 e sirp-alfa e para inibir o crescimento e/ou proliferação de tumores ou células tumorais | |
| MX2021002225A (es) | Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion. | |
| EP4495246A3 (en) | Techniques for generating cell-based therapeutics using recombinant t cell receptor genes | |
| WO2021016227A8 (en) | Synthetic genetic elements for biomanufacture | |
| MX2022013618A (es) | Cepa recombinante que produce l-lisina y metodos de construccion para la misma y uso de la misma. | |
| BR112023018832A2 (pt) | Composições de proteínas de fusão quiméricas modificadas e métodos de uso das mesmas | |
| BR112018014639A2 (pt) | expressão de múltiplos genes em microalgas | |
| BR112022012918A2 (pt) | Variantes de enzima de exaustão de metiltioadenosina/adenosina humana melhorada para terapia do câncer | |
| BR112021022742A2 (pt) | Método de expressão de proteínas de ligação de antígeno no sistema nervoso e uso de um construto de expressão | |
| MX382810B (es) | Mejora del metabolismo de microalga de xilosa. | |
| AR118696A1 (es) | Administración mejorada de vectores de tratamiento génico a células retinianas mediante el uso de una enzima glicósido hidrolasa | |
| BR112023023032A2 (pt) | Redirecionamento universal do hsv oncolítico | |
| BR112022007151A2 (pt) | Produção de bioproduto em uma célula hospedeira | |
| CO2021015432A2 (es) | Secuencia promotora y productos y usos relacionados de la misma |